Intellia Therapeutics and ONK Therapeutics have entered into a licensing and collaboration agreement to advance allogenic CRISPR-edited natural killer (NK) cell therapies for the treatment of patients with cancer. The deal, worth up to US$920 M, will leverage Intellia’s ex vivo genome editing technology and associated delivery technologies to develop up to five cell therapies. The agreement marks yet another deal driven by Intellia’s CRISPR platform, which has previously gained the attention of big pharma such as Novartis and Regeneron.